NEW YORK (GenomeWeb) – Horizon Discovery Group today announced an agreement to buy the CombinatoRx Service business of biopharmaceutical firm Zalicus for £4.74 million ($8.0 million).

CombinatoRx provides combination high-throughput screening (cHTS) services. Upon completion of the deal it will operate as a wholly owned subsidiary of Horizon and be called Horizon CombinatoRx. The new company will be located in a 23,000-square-foot facility in Cambridge, Mass.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.